ORGO icon

Organogenesis Holdings

3.18 USD
+0.00
0.00%
At close Dec 24, 4:00 PM EST
1 day
0.00%
5 days
-11.42%
1 month
-21.29%
3 months
9.28%
6 months
29.27%
Year to date
-22.06%
1 year
-19.90%
5 years
-36.40%
10 years
-67.38%
 

About: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Employees: 862

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

3% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 40

3% less funds holding

Funds holding: 115 [Q2] → 111 (-4) [Q3]

8.27% less ownership

Funds ownership: 56.17% [Q2] → 47.9% (-8.27%) [Q3]

13% less capital invested

Capital invested by funds: $209M [Q2] → $182M (-$26.9M) [Q3]

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $66K

Research analyst outlook

We haven’t received any recent analyst ratings for ORGO.

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
Organogenesis Expands Manufacturing Capacity to Support Future Growth
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island.
Organogenesis Expands Manufacturing Capacity to Support Future Growth
Neutral
GlobeNewsWire
1 month ago
Organogenesis Commends Final LCDs
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination
Organogenesis Commends Final LCDs
Neutral
Seeking Alpha
1 month ago
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ross Osborne - Cantor Fitzgerald Ryan Zimmerman - BTIG Operator Please stand by. Welcome ladies and gentlemen to the Third Quarter of Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode.
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
Organogenesis (ORGO) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
Neutral
GlobeNewsWire
1 month ago
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Neutral
GlobeNewsWire
2 months ago
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th.
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
Positive
Zacks Investment Research
2 months ago
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock
Neutral
GlobeNewsWire
2 months ago
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
CANTON, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of “Dehydrated Amnion Chorion Membrane Versus Standard of Care for Diabetic Foot Ulcers: A Randomised Controlled Trial” in the Journal of Wound Care.
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
Neutral
GlobeNewsWire
3 months ago
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences:
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
Charts implemented using Lightweight Charts™